Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...
Eucure Biopharma Doses First Patient in YH003 + Keytruda Trial for Mucosal Melanoma
Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...
Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL
Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...
Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...
Neurophth and Abogen Partner on mRNA Therapy for Retinal Diseases
China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...
Hong Kong Researchers Explore TES for Depression and Alzheimer’s Treatment
Researchers at The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and...
CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development
US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...
Sinopharm in Talks to Acquire BBI Life Sciences in USD 1B+ Deal
China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based...
Acer Therapeutics and Relief Therapeutics Awarded China Patent for ACER-001
US-based Acer Therapeutics Inc. (Nasdaq: ACER) and Swiss partner Relief Therapeutics Holding SA (SWX: RLF)...
Bangbang Robot Raises USD 14.9M in Series B to Expand Mobility Tech
Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB...
OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC
Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...
Hengrui Medicine’s SHR8554 Accepted for NMPA Review in Postoperative Pain
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its market filing for SHR8554,...
Insilico Medicine Identifies Novel ALS Therapeutic Targets via AI Platform PandaOmics
China-based Insilico Medicine announced the identification of multiple novel therapeutic targets for amyotrophic lateral sclerosis...
CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an...
Gan & Lee Pharmaceuticals’ GZR4 Ultra-Long-Acting Insulin Receives Clinical Trial Approval
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that its Category 1 therapeutic biologic product...
Aden Secures USD 29.8M Series B+ Funding to Expand DRG/DIP Solutions
Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB...
NMPA Issues New Vaccine Manufacturing and Distribution Rules
China’s National Medical Products Administration (NMPA) has released the “Vaccine Manufacturing and Distribution Management Measures,”...
VivaVision Biotech’s VVN539 Enters Phase II Trial for Open-Angle Glaucoma in US
China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study...
Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact
Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...
Hangzhou DAC Bio Partners with Janssen on ADC Development Deal
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...